Opportunities and Challenges of Cross-border M&A? ARC Capital partners invited to speak at China M&A Summit

Opportunities and Challenges of Cross-border M&A? ARC Capital partners invited to speak at China M&A Summit

On January 14, 2020, our partner, Sergio Camarero, was invited to speak at The 17th China M&A summit 2020, hosted by The Global Initiator Consulting Group.

The meeting aims to enhance the practicality and techniques as well as prevent the potential risks of cross-border mergers and acquisitions. The conference invited a number of experts to share their insights. Especially amidst the global economic downturn, the scope of cross-border mergers and acquisitions are expected to fall from $2.8 trillion in 2019 to $2.1 trillion in 2020. Globally, many investors and companies with capital are on the sidelines, waiting for the opportunity to advance both domestic and cross-border mergers and acquisitions. The conference also discusses, how to maximize the probability of successful mergers and acquisitions, how to ensure the success of cross-border transactions through mature strategies and solutions. The conference participants include: Bao Steel Group, Amco, Ernst & Young, Zhonglun Law Firm and other recognised firms.

Our partner, Sergio Camarero, discussed the recent changes in the global and Chinese M&A space, the M&A global market, M&A China trends & opportunities. Hot topics include Capital Liquidity, China’s overall competitiveness, changes in the regulatory environment, changes in China’s domestic market and business climate, and the increasing openness to the outside world. Also, the challenges and strategies that companies will face in cross-border M&A, such as the US-China trade war, capital restrictions and cultural differences was heavily discussed. Finally, he shared ARC’s recent cross-border M&A case studies.

Contact ARC Capital ([email protected]) to further discuss your views and specific needs on cross-border mergers and acquisitions, or to obtain the conference materials.

Continue reading

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

HONG KONG, 18 June 2026 — ARC Group today announced that it has committed to invest in Cloudbreak Pharma Inc. (HKEX: 2592), a clinical-stage ophthalmology biotechnology company with operations across the United States and China, following the signing of a share subscription agreement through its wholly owned subsidiary ARC Group International Limited. The transaction marks […]
Rising Together | ARC Dragon Boat Team Takes to the Water
Bio Green Med Solution, Inc. Announces Business Combination Agreement to Acquire Future NRG Sdn. Bhd.
Inside ARC Group | University of Nottingham Ningbo China

Please complete this form to download the case study

This field is for validation purposes and should be left unchanged.
*Required before submission